Pinkal Desai1, Robert Wallace2, Matthew L Anderson3, Barbara V Howard4, Roberta M Ray5, Chunyuan Wu5, Monika Safford6, Lisa W Martin7, Thomas Rohan8, JoAnn E Manson9, Michael S Simon10. 1. Weill Cornell Medical College, New York, NY, United States. Electronic address: pid9006@med.cornell.edu. 2. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, United States. 3. Baylor College of Medicine, Houston, TX, United States. 4. MedStar Health Research Institute and Georgetown/Howard Universities Center for Clinical and Translational Science, Washington, DC, United States. 5. Fred Hutchinson Cancer Research Center, Seattle, WA. 6. Weill Cornell Medical College, New York, NY, United States. 7. University of Alabama, School of Public Health, Birmingham, AL, United States; George Washington University, Washington, DC, United States. 8. Albert Einstein College of Medicine, Bronx, NY, United States. 9. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States. 10. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States.
Abstract
BACKGROUND: Statins have anti proliferative activity in vitro against endometrial and ovarian cancer and can affect levels of reproductive hormones. We analyzed data from the Women's Health Initiative (WHI) to assess whether statins are associated with risk of endometrial and ovarian cancer. METHODS: The WHI study included 161,808 postmenopausal women in which incident cases of endometrial (n = 1377) and ovarian cancer (n = 763) were identified over an average of 10.8 (SD + 3.3) years. Information on statin use and risk factors was collected at baseline and follow-up. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association of statin use and risk of endometrial and ovarian cancer. All statistical tests were two-sided. RESULTS: Statins were used at baseline by 7.5% women and by up to 25% at year nine. The multivariable adjusted HR for risk of endometrial cancer for baseline statin use was 0.74, 95% C.I. 0.59-0.94 and for ovarian cancer was 1.15, 95% C.I. 0.89-1.50. In time-dependent models, statins were not associated with endometrial cancer (HR 0.91, 95% C.I. 0.76-1.08) however there was an increased risk of ovarian cancer (HR 1.30, 95% CI 1.04-1.62), largely attributed to the effect of the hydrophilic statin, pravastatin (1.89, 95% CI 1.24-2.88). CONCLUSIONS: There was a reduction in risk of endometrial cancer among statin users at baseline but not in time-dependent models. Pravastatin use was associated with an increased risk of ovarian cancer. Analyses of larger numbers of cases are needed to evaluate these findings.
BACKGROUND: Statins have anti proliferative activity in vitro against endometrial and ovarian cancer and can affect levels of reproductive hormones. We analyzed data from the Women's Health Initiative (WHI) to assess whether statins are associated with risk of endometrial and ovarian cancer. METHODS: The WHI study included 161,808 postmenopausal women in which incident cases of endometrial (n = 1377) and ovarian cancer (n = 763) were identified over an average of 10.8 (SD + 3.3) years. Information on statin use and risk factors was collected at baseline and follow-up. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) for the association of statin use and risk of endometrial and ovarian cancer. All statistical tests were two-sided. RESULTS: Statins were used at baseline by 7.5% women and by up to 25% at year nine. The multivariable adjusted HR for risk of endometrial cancer for baseline statin use was 0.74, 95% C.I. 0.59-0.94 and for ovarian cancer was 1.15, 95% C.I. 0.89-1.50. In time-dependent models, statins were not associated with endometrial cancer (HR 0.91, 95% C.I. 0.76-1.08) however there was an increased risk of ovarian cancer (HR 1.30, 95% CI 1.04-1.62), largely attributed to the effect of the hydrophilic statin, pravastatin (1.89, 95% CI 1.24-2.88). CONCLUSIONS: There was a reduction in risk of endometrial cancer among statin users at baseline but not in time-dependent models. Pravastatin use was associated with an increased risk of ovarian cancer. Analyses of larger numbers of cases are needed to evaluate these findings.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Jane A Cauley; Anne McTiernan; Rebecca J Rodabough; Andrea LaCroix; Douglas C Bauer; Karen L Margolis; Electra D Paskett; Mara Z Vitolins; Curt D Furberg; Rowan T Chlebowski Journal: J Natl Cancer Inst Date: 2006-05-17 Impact factor: 13.506
Authors: Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero Journal: Biomedicines Date: 2021-12-31